On August 5, Evolus (NASDAQ:EOLS) reported second-quarter 2026 results that showed the company finally translating years of growth into the bottom line. Global net revenue reached $84.1 million, up 21% over the prior year, and the company followed that up by raising its full-year 2026 outlook. The quarter also marked the third straight period of positive Adjusted EBITDA, a milestone the aesthetics company has been chasing since it entered the crowded injectables market.
Turning Growth Into Real Profit
The headline number was profitability. Adjusted EBITDA came in at $4.7 million for the quarter, a $12.6 million swing from the $7.9 million loss posted in the second quarter of 2025. GAAP operating loss narrowed to $4.5 million from $10.2 million a year earlier, showing the improvement is not just an accounting adjustment but a real reduction in cash burn. Revenue for the quarter split between $75.2 million from global toxin sales and $8.9 million from injectable hyaluronic acid gels, and management raised full-year 2026 revenue guidance to a range of $330 million to $337 million, up from $327 million to $337 million, while also lifting adjusted gross profit margin guidance to 67.0% to 67.5%.
That financial progress is backed by real customer traction. Total purchasing accounts grew by roughly 600 in the quarter, and more than 18,600 customers have bought from Evolus since launch, pushing US account penetration above 60%. Reorder rates topped 70%, and the Evolus Rewards loyalty program added over 77,000 members to surpass 1.5 million, a 25% jump from a year earlier, with redemptions hitting an all-time high above 270,000. On the pipeline side, Evolus is diversifying beyond its core toxin business. It launched its full Estyme collection of HA gels across Europe, struck a licensing deal with Symatese to bring Estyme to Canada, Australia and New Zealand by 2028, and signed an exclusive U.S. agreement with IBSA to commercialize Profhilo, a skin quality injectable the company estimates could generate more than $100 million in peak annual revenue once it reaches the U.S. market in 2030.
Growth Still Comes With A Price Tag
The improvement has limits. Even with the narrower loss, Evolus is still not GAAP profitable, and operating expenses kept climbing sequentially, with GAAP opex at $61.7 million versus $55.7 million in the first quarter and non-GAAP opex at $53.3 million versus $49.1 million. Cash and cash equivalents fell to $45.2 million as of June 30, 2026, down from $49.8 million three months earlier, even as the company reaffirmed a full-year Adjusted EBITDA margin outlook of just low to mid single digits.
The newest growth bets also carry long timelines. Profhilo will not reach US commercialization until 2030, and the expanded Estyme markets are not expected to launch until 2028, meaning today’s deal announcements will not show up in revenue for years. Guidance for 2026 also assumes zero contribution from Evolysse Sculpt, even though the company anticipates FDA approval in the fourth quarter, leaving a real catalyst deliberately excluded from the numbers investors are working with.
What The Market Is Pricing In
Hedge fund ownership held steady at 24 funds in the most recent quarter compared to 24 the quarter before, showing no shift in institutional conviction either way. Short interest sits at 8.97% of float, a level that reflects meaningful skepticism without signaling a heavily crowded bearish trade. The stock trades at a forward P/E of 19.80, as of September 9, a multiple that assumes continued earnings improvement rather than pricing in a stumble.
Building Toward A Bigger Payoff
Evolus has proven it can grow revenue and narrow losses at the same time, and its reaffirmed 2028 targets of $450 million to $500 million in revenue and 13% to 15% Adjusted EBITDA margins give investors a long-term yardstick. The bulls can point to three straight quarters of positive Adjusted EBITDA and a widening product portfolio as evidence the model is working. The bears can point to declining cash, rising expenses, and payoffs pushed out to 2028 and 2030 as reasons to wait.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
Hedge Fund Resource Center